Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
| Autor: | Ollier, Romain, Wassmann, Paul, Monney, Thierry, Ries Fecourt, Christelle, Gn, Sunitha, C A, Vinu, Ayoub, Daniel, Stutz, Cian, Gudi, Girish S, Blein, Stanislas |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Protein G
purification engineering Immunology bispecific BEAT 03 medical and health sciences 0302 clinical medicine Neonatal Fc receptor Bacterial Proteins Report heterodimer Antibodies Bispecific Humans Immunology and Allergy Avidity Binding site Staphylococcal Protein A Antibody 030304 developmental biology 0303 health sciences biology Chemistry T-cell receptor Antibodies Monoclonal In vitro Immunoglobulin Fc Fragments HEK293 Cells Biochemistry 030220 oncology & carcinogenesis biology.protein Protein A |
| Zdroj: | mAbs |
| ISSN: | 1942-0870 1942-0862 |
| Popis: | Heavy chain (Hc) heterodimers represent a majority of bispecific antibodies (bsAbs) under clinical development. Although recent technologies achieve high levels of Hc heterodimerization (HD), traces of homodimer contaminants are often present, and as a consequence robust purification techniques for generating highly pure heterodimers in a single step are needed. Here, we describe two different purification methods that exploit differences in Protein A (PA) or Protein G (PG) avidity between homo- and heterodimers. Differential elution between species was enabled by removing PA or PG binding in one of the Hcs of the bsAb. The PA method allowed the avidity purification of heterodimers based on the VH3 subclass, which naturally binds PA and interferes with separation, by using a combination of IgG3 Fc and a single amino acid change in VH3, N82aS. The PG method relied on a combination of three mutations that completely disrupts PG binding, M428G/N434A in IgG1 Fc and K213V in IgG1 CH1. Both methods achieved a high level of heterodimer purity as single-step techniques without Hc HD (93–98%). Since PA and PG have overlapping binding sites with the neonatal Fc receptor (FcRn), we investigated the effects of our engineering both in vitro and in vivo. Mild to moderate differences in FcRn binding and Fc thermal stability were observed, but these did not significantly change the serum half-lives of engineered control antibodies and heterodimers. The methods are conceptually compatible with various Hc HD platforms such as BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor), in which the PA method has already been successfully implemented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|